ELN — Elanix Biotechnologies AG Share Price
- €0.43m
- €0.39m
- €0.06m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | n/a | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 11.57 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | n/a | ||
Return on Equity | -30.78% | ||
Operating Margin | -4928.99% |
Financial Summary
Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | €m | n/a | n/a | 0.01 | 0.23 | 0.06 | 3.52 | 7.49 | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.
Directors
- Last Annual
- December 31st, 2018
- Last Interim
- June 30th, 2019
- Incorporated
- March 26th, 1997
- Public Since
- November 16th, 1998
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Frankfurt Stock Exchange
- Shares in Issue
- 8,080,902
- Address
- Hanauer Landstrasse 291 B, FRANKFURT AM MAIN, 60314
- Web
- https://www.elanixbiotechnologies.ch/
- Phone
- +49 61171627677
- Auditors
- Baker Tilly
Upcoming Events for ELN
Similar to ELN
4Sc AG
Frankfurt Stock Exchange
CureVac NV
Frankfurt Stock Exchange
Deutsche Biotech Innovativ AG
Frankfurt Stock Exchange
Diagonal Bio AB
Frankfurt Stock Exchange
Medpace Holdings
Frankfurt Stock Exchange
FAQ
As of Today at 01:07 UTC, shares in Elanix Biotechnologies AG are trading at €0.05. This share price information is delayed by 15 minutes.
Shares in Elanix Biotechnologies AG last closed at €0.05 and the price had moved by -66.67% over the past 365 days. In terms of relative price strength the Elanix Biotechnologies AG share price has underperformed the FTSE Global All Cap Index by -69.46% over the past year.
The overall consensus recommendation for Elanix Biotechnologies AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Elanix Biotechnologies AG does not currently pay a dividend.
Elanix Biotechnologies AG does not currently pay a dividend.
Elanix Biotechnologies AG does not currently pay a dividend.
To buy shares in Elanix Biotechnologies AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.05, shares in Elanix Biotechnologies AG had a market capitalisation of €0.40m.
Here are the trading details for Elanix Biotechnologies AG:
- Country of listing: Germany
- Exchange: FRA
- Ticker Symbol: ELN
Based on an overall assessment of its quality, value and momentum Elanix Biotechnologies AG is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Elanix Biotechnologies AG is €6.39. That is 12680% above the last closing price of €0.05.
Analysts covering Elanix Biotechnologies AG currently have a consensus Earnings Per Share (EPS) forecast of -€0.29 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Elanix Biotechnologies AG. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -51.29%.
As of the last closing price of €0.05, shares in Elanix Biotechnologies AG were trading -49.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Elanix Biotechnologies AG PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Elanix Biotechnologies AG's directors